×
More Charts Below
AtriCure Income from Continuous Operations 2010-2024 | ATRC
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Recent Trends
AtriCure income from continuous operations from 2010 to 2024. Income from continuous operations can be defined as a company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change
Related Stocks
Company Name
Market
Cap
Abbott Laboratories (ABT)
$227.2B
Boston Scientific (BSX)
$140.7B
Stryker (SYK)
$132.3B
EssilorLuxottica (ESLOY)
$128.4B
Medtronic (MDT)
$105.9B
Lonza Group Ag (LZAGY)
$47.4B
Haleon (HLN)
$46.2B
ResMed (RMD)
$31.3B
Agilent Technologies (A)
$29.2B
GE HealthCare Technologies (GEHC)
$28.6B
Terumo (TRUMY)
$28.2B
Koninklijke Philips (PHG)
$22.2B
Zimmer Biomet Holdings (ZBH)
$19.4B
Insulet (PODD)
$17.3B
Baxter (BAX)
$14.8B
Smith & Nephew SNATS (SNN)
$11.4B
Sunny Optical Technology (SNPTF)
$7.6B
Lantheus Holdings (LNTH)
$6.9B
Bio-Rad Laboratories (BIO)
$6.7B
Demant (WILYY)
$6.6B
Prestige Consumer Healthcare (PBH)
$4B
Shandong Weigao Medical Polymer (SHWGF)
$3.5B
Perrigo (PRGO)
$3.5B
ICU Medical (ICUI)
$3.4B
Haemonetics (HAE)
$2.9B
Envista Holdings (NVST)
$2.6B
GN Store Nord (GNNDY)
$2.2B
LeMaitre Vascular (LMAT)
$1.9B
QuidelOrtho (QDEL)
$1.7B
Kestra Medical Technologies (KMTS)
$1.2B